The novel tribody [(CD20)2xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells-Reference-Cited by-同舟云学术

The novel tribody [(CD20)2xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells

Published:2012-06-04 Issue:1 Volume:27 Page:190-201
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Glorius P,Baerenwaldt A,Kellner C,Staudinger M,Dechant M,Stauch M,Beurskens F J,Parren P W H I,Winkel J G J van de,Valerius T,Humpe A,Repp R,Gramatzki M,Nimmerjahn F,Peipp M

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2012150.pdf

Reference60 articles.

1. Lim SH, Beers SA, French RR, Johnson PW, Glennie MJ, Cragg MS . Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica 2010; 95: 135–143.

2. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825–2833.

3. Brugger W, Hirsch J, Grunebach F, Repp R, Brossart P, Vogel W et al. Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study. Ann Oncol 2004; 15: 1691–1698.

4. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235–242.

5. Ball ED, Broome HE . Monoclonal antibodies in the treatment of hematologic malignancy. Best Pract Res Clin Haematol 2010; 23: 403–416.

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune Cell Influence on Diffuse Large B-Cell Lymphoma: A Mendelian Randomization Analysis;2024-09-10

2. Tri-specific killer engager: unleashing multi-synergic power against cancer;Exploration of Targeted Anti-tumor Therapy;2024-04-25

3. Targeting natural killer cells: from basic biology to clinical application in hematologic malignancies;Experimental Hematology & Oncology;2024-02-23

4. Optimizing chemotherapy treatment outcomes using metaheuristic optimization algorithms: A case study;Bio-Medical Materials and Engineering;2023-12-21

5. Novel NKG2D-directed bispecific antibodies enhance antibody-mediated killing of malignant B cells by NK cells and T cells;Frontiers in Immunology;2023-10-27